← Back to Clinical Trials
Recruiting NCT06326892

NCT06326892 Natural Orifice Specimen Extraction in Low Rectal Cancer Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06326892
Status Recruiting
Phase
Sponsor Istituto Clinico Humanitas
Condition Rectal Cancer
Study Type OBSERVATIONAL
Enrollment 350 participants
Start Date 2023-07-31
Primary Completion 2024-05-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Natural Orifice Specimen Extraction (NOSE)Traditional specimen extraction

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 350 participants in total. It began in 2023-07-31 with a primary completion date of 2024-05-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the postoperative outcomes of low rectal cancer patients who underwent surgery with Natural Orifice Specimen Extraction (NOSE) versus traditional Pfannenstiel extraction.

Eligibility Criteria

Inclusion Criteria: * Patients undergoing low anterior resection with Total Mesorectal Excision (TME) for low rectal cancer between January 2017 and January 2023 * Patients with rectal cancer classified as "low" according to the English National Low Rectal Cancer Development Programme (LOREC) Exclusion Criteria: * Patients undergoing non-restorative procedures * Patients undergoing immediate or delayed handsewn coloanal anastomosis * Patients undergoing planned open surgery or unplanned conversion from minimally invasive to open surgery * Patients with a concomitant diagnosis of Inflammatory Bowel Disease (IBD)

Contact & Investigator

Central Contact

Annalisa Maroli, PhD

✉ colorapp@humanitas.it

📞 02 8224 7776

Principal Investigator

Antonino Spinelli, MD, PhD

PRINCIPAL INVESTIGATOR

IRCCS Huamanitas Research Hospital

Frequently Asked Questions

Who can join the NCT06326892 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Rectal Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06326892 currently recruiting?

Yes, NCT06326892 is actively recruiting participants. Contact the research team at colorapp@humanitas.it for enrollment information.

Where is the NCT06326892 trial being conducted?

This trial is being conducted at Rozzano, Italy.

Who is sponsoring the NCT06326892 clinical trial?

NCT06326892 is sponsored by Istituto Clinico Humanitas. The principal investigator is Antonino Spinelli, MD, PhD at IRCCS Huamanitas Research Hospital. The trial plans to enroll 350 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology